Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. - Wikidata - wikimedia - TriplyDB

Rituximab: the first monoclonal antibody approved for the treatment of lymphoma.

Rituximab: the first monoclonal antibody approved for the treatment of lymphoma.

http://www.wikidata.org/entity/Q34084727

about

Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect In vivo, multimodal imaging of B cell distribution and response to antibody immunotherapy in mice Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus.Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkin's lymphoma (B-NHL) chemotherapy: a meta-analysis.Administration of anti-CD20 mAb is highly effective in preventing but ineffective in treating chronic graft-versus-host disease while preserving strong graft-versus-leukemia effects Molecular regulation of JC virus tropism: insights into potential therapeutic targets for progressive multifocal leukoencephalopathy.Cancer immunotherapy in clinical practice -- the past, present, and future.Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody.γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development.Immune microenvironment in tumor progression: characteristics and challenges for therapy Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan.Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates.Omacetaxine mepesuccinate induces apoptosis and cell cycle arrest, promotes cell differentiation, and reduces telomerase activity in diffuse large B‑cell lymphoma cells.Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies.Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others.Biological therapy in systemic lupus erythematosus.A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells Rationale and efficacy for the use of rituximab in paraneoplastic pemphigus

P2860

Q26775720-62E1C7BA-BE21-4C11-A1AD-502D79740AD0 Q26826830-2CA64026-BB39-4682-8C2C-E6BD9D32F918 Q28752150-24834032-243F-44B1-95DC-794042888DB3 Q33421410-44F1FDF8-5C48-4A38-8738-7BB62D9C094F Q33421964-6CB04A12-0A90-4ED8-BA0E-DB546BBFEAA7 Q33905411-400B9D7A-57F0-493A-8012-9F86183A047D Q34110804-FC12A1EE-98D8-4C55-BFAD-30E0B7F785C7 Q34309399-3CE2574A-1022-4FCD-B3F4-0333B70B8BC3 Q34585485-6CC5B54E-1E41-4CA0-A01D-248EDB038B86 Q34612619-1FE80911-0EEC-46B5-BA31-49F4ECA9732B Q35498227-AADA1D03-7854-45DD-A64C-19395AE4C900 Q36178400-1D3A5548-627F-4EFB-A704-27D7704A55DE Q36993242-41B30A6A-DB41-4F9A-AB5E-D57A8A0E8402 Q37129235-B2D9430E-147E-471C-A681-32044506F2D0 Q37661559-A5864D86-0737-4E6B-84B8-558224A761D2 Q38096425-F27C7411-B891-4429-B876-59DE5BACCD20 Q38286209-2AD2A564-04E3-4136-B6CC-739B1954F257 Q38789476-C8DD8786-6176-4D3D-9AF6-434C8EB68D84 Q38795442-630AC364-90FE-4F58-B02A-AD1E785B08E7 Q38817467-594A1BFB-30C7-49E0-B308-BBB53AAD8F6E Q39157881-90EC0B42-2871-4C12-978C-87A73AF4C195 Q42141973-33D72420-C0BE-4821-A0D3-FB63708C9BCE Q42601428-1FCA1B4E-DA8D-4212-90AE-60A851C0C7B6 Q58482127-F1B8AB8B-B0DF-429E-9B8F-CF2CD9FEDCFA

P2860

Rituximab: the first monoclonal antibody approved for the treatment of lymphoma.

http://www.wikidata.org/entity/Q34084727

description

2000 nî lūn-bûn

@nan

2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Rituximab: the first monoclonal antibody approved for the treatment of lymphoma.

@ast

Rituximab: the first monoclonal antibody approved for the treatment of lymphoma.

@en

Rituximab: the first monoclonal antibody approved for the treatment of lymphoma.

@nl

type

label

Rituximab: the first monoclonal antibody approved for the treatment of lymphoma.

@ast

Rituximab: the first monoclonal antibody approved for the treatment of lymphoma.

@en

Rituximab: the first monoclonal antibody approved for the treatment of lymphoma.

@nl

prefLabel

Rituximab: the first monoclonal antibody approved for the treatment of lymphoma.

@ast

Rituximab: the first monoclonal antibody approved for the treatment of lymphoma.

@en

Rituximab: the first monoclonal antibody approved for the treatment of lymphoma.

@nl

P1433

Q34084727-6C41DD22-0DFF-4220-BBFB-F98B02E9A31C

P1476

Q34084727-43248ECE-4B13-4F6C-8718-F69645719933

P2093

Q34084727-2C93BE91-0066-4483-8722-B3297135B9AB

Q34084727-4283CC35-A73F-4A56-BFEE-BC41A605A202

Q34084727-77558193-09D8-46BC-9907-32AF26C90E28

Q34084727-84BD6F4B-7918-4BF7-8072-9F56D9859B35

Q34084727-B18418E1-53EE-4C0E-B12D-D10F3633A244

Q34084727-B24386C0-7573-4A5C-8358-93156EDD6CCF

Q34084727-BD0FC7D5-E07A-4933-9FAB-E3E141CD31DC

Q34084727-D4FEC573-2E7D-4C9B-9A51-97A6EFF6D60B

Q34084727-E046CC54-07FB-46A8-BDB6-BAFB62E527A9

Q34084727-E11A27B5-1D5F-4835-82C0-4E18E1E62571

P304

Q34084727-B51E3E11-05BF-47B6-9C95-F84D006EB4CB

P31

Q34084727-543FC427-0E14-4588-AC7E-3E7B6EEC6BD1

P356

Q34084727-4F833ED3-BCB7-4078-B80F-2B24095F097F

P433

Q34084727-F8E5687A-04C6-4201-8007-44787D209C4D

P478

Q34084727-233D7657-3732-4B21-BB3A-5885C9C35140

P577

Q34084727-F4528A50-401D-4481-AFB0-81BF40672961

P5875

Q34084727-602BD4D0-C3BB-4AE9-B637-4712D3B8F39B

P698

Q34084727-B406B871-B7AE-4394-927F-B5FB517344F0

P921

Q34084727-C70A2210-F8A6-47EF-B7DC-51F8A574DD99

P356

1389201003379059

P1433

Current Pharmaceutical Biotechnology

P1476

Rituximab: the first monoclonal antibody approved for the treatment of lymphoma.

@en

P2093

Cairelli S

http://www.w3.org/2001/XMLSchema#string

Dallaire BK

http://www.w3.org/2001/XMLSchema#string

Grillo-López AJ

http://www.w3.org/2001/XMLSchema#string

Leonard JE

http://www.w3.org/2001/XMLSchema#string

McClure A

http://www.w3.org/2001/XMLSchema#string

Rosenberg J

http://www.w3.org/2001/XMLSchema#string

Shen CD

http://www.w3.org/2001/XMLSchema#string

Varns CL

http://www.w3.org/2001/XMLSchema#string

Weaver R

http://www.w3.org/2001/XMLSchema#string

Wei A

http://www.w3.org/2001/XMLSchema#string

P304

1-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/1389201003379059

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2000-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11875692

http://www.w3.org/2001/XMLSchema#string

P698

11467356

http://www.w3.org/2001/XMLSchema#string

P921